Navigate this market better. Subscribe for FREE stock alerts and information.

Wednesday, May 14, 2014

Senators urge U.S. anti-trust review of Pfizer-AstraZeneca plan, (NYSE: AZN)

Six U.S. senators have asked the Federal Trade Commission and the Department of Justice to look at what they termed the anti-trust and anti-consumer implications of Pfizer's Inc potential takeover of UK's AstraZeneca PLC. "Pfizer's record of reducing efforts to innovate and bring new products to market following prior acquisitions is plain," the senators, all Democrats, wrote to the agencies' top officials.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. Shares of AZN fell by 0.09% or $-0.07/share to $78.29. In the past year, the shares have traded as low as $46.87 and as high as $82.68. On average, 4030250 shares of AZN exchange hands on a given day and today's volume is recorded at 4813822.



Source